Cue Biopharma, Inc. (CUE)

Cue Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	22.46	48.51	51.61	64.37	74.87
Short-Term Investments	0.93	-	24.68	-	10
Cash & Short-Term Investments	23.39	48.51	76.29	64.37	84.87
Cash Growth	-51.79%	-36.41%	18.52%	-24.15%	42.85%
Receivables	0.95	1.7	0.06	3.14	1.42
Prepaid Expenses	0.81	1.24	0.84	0.87	1.24
Other Current Assets	-	-	-	0.08	-
Total Current Assets	25.14	51.45	77.19	68.47	87.53
Property, Plant & Equipment	4.84	7.12	10.7	11.92	8.88
Other Long-Term Assets	2.21	2.96	3.39	3.01	3.12
Total Assets	32.19	61.53	91.28	83.4	99.53
Accounts Payable	2.82	3.5	2.73	2.59	2.07
Accrued Expenses	2.91	4.14	3.55	4.62	2.79
Current Portion of Long-Term Debt	4.33	3.96	1.96	-	-
Current Portion of Leases	3.54	3.37	3.3	4.93	4.78
Current Unearned Revenue	0.09	2.11	-	0.65	6.68
Other Current Liabilities	-	-	-	0	-
Total Current Liabilities	13.69	17.08	11.55	12.79	16.32
Long-Term Debt	-	4.2	8.04	-	-
Long-Term Leases	1	3.16	6.02	5.12	2.37
Long-Term Unearned Revenue	-	-	-	-	1.94
Total Liabilities	14.69	24.45	25.6	17.91	20.62
Common Stock	0.06	0.05	0.04	0.03	0.03
Additional Paid-In Capital	359.3	338.23	316.19	262.91	232.16
Retained Earnings	-341.86	-301.19	-250.46	-197.45	-153.29
Comprehensive Income & Other	-	-	-0.1	-	0.01
Shareholders' Equity	17.5	37.09	65.68	65.49	78.91
Total Liabilities & Equity	32.19	61.53	91.28	83.4	99.53
Total Debt	8.88	14.7	19.32	10.05	7.15
Net Cash (Debt)	14.51	33.82	56.97	54.32	77.72
Net Cash Growth	-57.09%	-40.64%	4.89%	-30.11%	44.97%
Net Cash Per Share	0.26	0.74	1.60	1.74	2.71
Filing Date Shares Outstanding	61.82	48.64	43.17	33.01	30.46
Total Common Shares Outstanding	61.82	47.22	43.04	32.2	30.35
Working Capital	11.45	34.37	65.64	55.68	71.21
Book Value Per Share	0.28	0.79	1.53	2.03	2.60
Tangible Book Value	17.5	37.09	65.68	65.49	78.91
Tangible Book Value Per Share	0.28	0.79	1.53	2.03	2.60
Machinery	-	4.29	5.62	5.55	4.51
Construction In Progress	-	-	-	-	0.41
Leasehold Improvements	-	0.12	0.12	0.01	-

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q